🇺🇸 FDA
Pipeline program

PTR-01

PTR-01-003

Phase 2 small_molecule completed

Quick answer

PTR-01 for Recessive Dystrophic Epidermolysis Bullosa is a Phase 2 program (small_molecule) at BridgeBio Oncology Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
BridgeBio Oncology Therapeutics
Indication
Recessive Dystrophic Epidermolysis Bullosa
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials